GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Dec 9, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Dec 9, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 13 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
Related Tickers: GSK
TL;DR
GSK bought back some of its own stock via BNP Paribas.
AI Summary
GSK plc announced on December 9, 2025, that it has purchased a certain number of its own ordinary shares through its broker, BNP Paribas SA. The filing does not specify the exact number of shares or the total dollar amount involved in this transaction.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not contain significant new financial or operational information.
Key Players & Entities
- GSK plc (company) — The company making the share purchase.
- BNP Paribas SA (company) — The broker acting on behalf of GSK plc for the share purchase.
FAQ
What is the total number of GSK plc ordinary shares purchased?
The filing states that a 'certain number' of ordinary shares were purchased but does not provide a specific quantity.
What is the total dollar amount spent on the share repurchase?
The filing does not disclose the total dollar amount of the share repurchase.
On what date did GSK plc announce this transaction?
GSK plc announced the transaction on December 9, 2025.
Through which financial institution did GSK plc conduct these share purchases?
GSK plc acted through its broker, BNP Paribas SA.
What is the par value of GSK plc's ordinary shares mentioned in the filing?
The filing mentions the ordinary shares have a par value of 31 1/4 pence.
Filing Stats: 3,138 words · 13 min read · ~10 pages · Grade level 2.3 · Accepted 2025-12-09 06:34:50
Filing Documents
- a7208kgsk.htm (6-K) — 3291KB
- 0001654954-25-013768.txt ( ) — 3292KB
From the Filing
IN OWN SHARES a7208kgsk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934       For the month of December 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)       Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .       Transaction in own shares   GSK plc (the " Company ") announces today   acting through BNP Paribas SA (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase: 08 December 2025 Aggregate number of ordinary shares of  31¼  pence each purchased: 229,000 Lowest price paid per share (GBp): 1,803.00p Highest price paid per share (GBp): 1,822.00p Volume-weighted average price paid per share (GBp): 1,814.42p   The purchased shares will be held   as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker, as announced on 30 September 2025. Since 30 September 2025, the Company has purchased 12,474,733 ordinary shares.   Following the above purchase, the Company will hold 237,939,577 ordinary shares in treasury and have 4,077,499,560 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,077,499,560. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 5.84 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.   Schedule of Purchases   Shares purchased:    GSK plc (ISIN: GB00BN7SWP63)   Date of purchases:      08 December 2025   Investment firm:         BNP Paribas SA     Aggregated information per trading venue: Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share)(GBp)   Lowest price paid (per ordinary share)(GBp)   Volume weighted average price paid (per ordinary share) (GBp)   BATE   24,598   1,821.00p   1,803.00p   1,814.65p   CHIX   65,438   1,821.00p   1,803.00p   1,813.56p   XLON   138,964   1,822.00p   1,803.00p   1,814.78p       Individual transactions:   Number of Shares   Price per Share (GBp)   Trading venue   Date of transaction   Time of transaction   Transaction reference number   6   1814.5   CHIX   08-Dec-2025   08:00:33   20251208158116176   175   1814.5   XLON   08-Dec-2025   08:00:33   20251208158116178   141   1813.0   CHIX   08-Dec-2025   08:01:00   20251208158116370   175   1813.0   XLON   08-Dec-2025   08:01:00   20251208158116372   157   1811.0   CHIX   08-Dec-2025   08:01:02   20251208158116386   175   1811.0   XLON   08-Dec-2025   08:01:02   20251208158116388   172   1812.5   CHIX   08-Dec-2025   08:02:09   20251208158116828   175   1812.5   XLON   08-Dec-2025   08:02:22   20251208158116992   11   1812.5   XLON   08-Dec-2025   08:02:22   20251208158116994   73   1814.0   XLON   08-Dec-2025   08:05:05